CORZ — Core Scientific Income Statement
0.000.00%
- $1.69bn
- $2.18bn
- $502.40m
- 32
- 30
- 59
- 35
Annual income statement for Core Scientific, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 59.5 | 60.3 | 544 | 640 | 502 |
Cost of Revenue | |||||
Gross Profit | 10.5 | 9.39 | 239 | 8.4 | 123 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 71.2 | 68 | 421 | 2,553 | 664 |
Operating Profit | -11.7 | -7.66 | 123 | -1,912 | -162 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -11.9 | -12.2 | 63.1 | -2,163 | -246 |
Provision for Income Taxes | |||||
Net Income After Taxes | -11.9 | -12.2 | 47.3 | -2,146 | -246 |
Net Income Before Extraordinary Items | |||||
Net Income | -11.9 | -12.2 | 47.3 | -2,146 | -246 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.9 | -22.7 | 47.3 | -2,146 | -246 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.04 | -0.086 | 0.251 | -3.09 | -0.354 |
Dividends per Share |